Hamide Nasiri

Hamide Nasiri

Auto-generated profile, based on publicly available information

Hamide Nasiri

Student Research Committee, School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 June 2025 in Metabolic Brain Disease
Verified
Journal Article
Closed access
PDF file
FGFarshad Goharmanesh
Farshad Goharmanesh
MMMaryam Masmoie
Maryam Masmoie
HNHamide Nasiri
Hamide Nasiri
SSSayedeh-Fatemeh Sadat-Madani
Sayedeh-Fatemeh Sadat-Madani
SNSara Montazeri Namin
Sara Montazeri Namin
FIFor The Alzheimer’s Disease Neuroimaging Initiative
For The Alzheimer’s Disease Neuroimaging Initiative

1 July 2025 in Molecular Brain
Verified
Journal Article
Open access
PDF file
AAAli Azargoonjahromi
Ali Azargoonjahromi
HNHamide Nasiri
Hamide Nasiri
Amyloid-β42 (Aβ42) regulates synaptic plasticity and memory formation at physiological levels in the brain, but in Alzheimer’s disease (AD), it can disrupt brain function and glucose metabolism. This disruption contributes to cognitive decline and neuropsychiatric symptoms, highlighting the need to better understand its complex effects. This study investigated the associations among cerebrospinal fluid (CSF) Aβ42 levels, cerebral glucose metabolism (assessed via FDG-PET), neuropsychiatric symptoms (evaluated using the NPI), and cognitive performance (measured by ADAS-Cog13 and MoCA) in individuals with AD, mild cognitive impairment (MCI), and cognitively normal (CN) participants. After adjusting for age, gender, education, and ApoE ɛ4 status, a significant positive relationship between CSF Aβ42 levels and cerebral glucose metabolism was observed in the MCI and AD groups, but not in the CN group. In the MCI group, higher cerebral glucose metabolism was associated with reductions in both neuropsychiatric and depressive symptoms, suggesting that higher glucose metabolism reflect higher activation state of investigated brain regions. In contrast, in the CN group, elevated CSF Aβ42 levels were directly linked to increased depressive symptoms, indicating that higher CSF Aβ42 may contribute to depression even in the absence of cognitive decline. Further analysis revealed that CSF Aβ42 levels were indirectly associated with reduced neuropsychiatric and depressive symptoms through enhanced cerebral glucose metabolism as mediator solely in the MCI group. Regarding cognitive performance, cerebral glucose metabolism showed a strong relationship with cognition in both the MCI and AD groups. Furthermore, higher CSF Aβ42 levels were positively associated with better cognitive performance in the MCI and AD groups, with cerebral glucose metabolism potentially mediating this relationship, while no effect was seen in the CN group. In short, CSF Aβ42 positively influenced cerebral glucose metabolism, which was linked to reduced neuropsychiatric and depressive symptoms as well as improved cognitive performance in MCI and AD groups.

25 November 2025 in Scientific Reports
Verified
Journal Article
Open access
HNHamide Nasiri
Hamide Nasiri
FKFarbod Khosravi
Farbod Khosravi
PSParsa Saberian
Parsa Saberian
MKMelika Kavian
Melika Kavian
MMMehrdad Mozafar
Mehrdad Mozafar
MBMaryam Bemanalizadeh
Maryam Bemanalizadeh
White matter hyperintensity (WMH), indicative of cerebral small vessel disease, has emerged as a potential biomarker for cognitive decline in Alzheimer's disease (AD). However, their predictive role across specific cognitive domains within the AD spectrum remains unclear. This study investigates the relationship between WMH volume and cognitive performance in memory, executive function, and language across the AD continuum. A cross-sectional analysis was conducted using data from the Alzheimer's Disease Neuroimaging Initiative (ADNI), comprising 557 participants categorized into cognitively normal (CN; n = 158), mild cognitive impairment (MCI; n = 334), and Alzheimer's dementia (AD; n = 65) groups. Cognitive function was assessed using composite scores for memory (ADNI-MEM), executive function (ADNI-EF), and language (ADNI-LAN). WMH volume was quantified through validated Bayesian segmentation of MRI data. Associations between cognitive scores and WMH volume, adjusted for age, gender, APOE ε4 status, and vascular risk factors, were evaluated via multiple linear regression analyses. WMH volume showed numerically progressive increases from CN to MCI and AD groups; however, between-group differences did not reach statistical significance. Within the MCI group, significant negative associations emerged between WMH volume and memory (β=-0.13, adjusted p = 0.045) and language scores (β=-0.12, adjusted p = 0.045). Conversely, these relationships were absent in both the CN and AD groups. WMH volume relates specifically to declines in memory and language abilities, particularly in individuals with MCI. These results support using WMH measurements as early markers to identify cognitive decline in AD, potentially helping to guide earlier diagnosis and treatment decisions.

8 May 2025 in Neuroscience
Verified
Journal Article
Closed access
HNHamide Nasiri
Hamide Nasiri
AAAli Azargoonjahromi
Ali Azargoonjahromi
ZNZahra Nouri
Zahra Nouri
SASayed Mehrdad Azimi
Sayed Mehrdad Azimi
HZHossein Zand
Hossein Zand
MMMahsa Mayeli
Mahsa Mayeli

6 August 2024 in medRxiv
Verified
Preprint
Open access
PDF file
AAAli Azargoonjahromi
Ali Azargoonjahromi
HNHamide Nasiri
Hamide Nasiri
FAFatemeh Abutalebian
Fatemeh Abutalebian
Resting-state EEG records brain activity when awake but not engaged in tasks, analyzing frequency bands linked to cognitive states. Recent studies on Alzheimer’s disease (AD) and frontotemporal dementia (FTD) have found a link between EEG activity, MMSE scores, and age, though some findings are conflicting. This study aimed to explore EEG regional differences among AD and FTD, thereby improving diagnostic strategies. We analyzed EEG recordings from 88 participants in OpenNeuro Dataset ds004504, collected at AHEPA General Hospital using a Nihon Kohden 2100 EEG device. The study used preprocessed recordings, classification algorithms, and cognitive function assessments (MMSE) to identify significant predictors and correlations between EEG measures and cognitive variables. The study revealed that cognitive function, age, and brain activity show distinct relationships in AD and FTD. In AD, MMSE scores significantly predicted brain activity in regions like C3, C4, T4, and Fz, with better cognitive performance linked to higher EEG power in frontal and temporal areas. Conversely, age had a major influence on brain activity in FTD, particularly in regions like C3, P3, O1, and O2, while MMSE scores did not significantly predict brain activity. In FTD, higher EEG power in regions like P3, P4, Cz, and Pz correlated with lower cognitive function. Thus, the findings suggest that EEG biomarkers can enhance diagnostic strategies by highlighting different patterns of brain activity related to cognitive function and age in AD and FTD.

1 April 2025 in BMC Neurology
Verified
Journal Article
Open access
PDF file
RNRezvan Nemati
Rezvan Nemati
ASAhmadreza Sohrabi-Ashlaghi
Ahmadreza Sohrabi-Ashlaghi
PSParsa Saberian
Parsa Saberian
MSMohammad Sadeghi
Mohammad Sadeghi
SMSajjad Mardani
Sajjad Mardani
HNHamide Nasiri
Hamide Nasiri
Growth-associated protein 43 (GAP-43) is a key protein involved in neuronal growth and synaptic plasticity. Alterations in GAP-43 levels have been associated with Alzheimer’s Disease (AD), potentially reflecting synaptic dysfunction. We evaluated the potential of GAP-43 as a biomarker for AD and explored its association with amyloid-beta (Aβ) levels, as well as its correlation with Aβ plaque burden in the brain. We screened 1,639 participants from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) cohort. A total of 226 individuals met the eligibility criteria and were enrolled. Participants were classified into three groups: 77 cognitively normal (CN) individuals, 111 with mild cognitive impairment (MCI), and 38 with a diagnosis of AD. The associations between cerebrospinal fluid (CSF) GAP-43 levels with other biomarkers as well as [¹⁸F] AV-45 (Florbetapir) PET Standardized Uptake Value Ratios (SUVR) were investigated. Our findings revealed significantly elevated CSF GAP-43 levels in individuals with AD compared to CN and MCI groups. Furthermore, GAP-43 levels showed a significant positive correlation with tau pathology. Notably, we observed a significant association between GAP-43 and [¹⁸F] Florbetapir PET SUVR in the MCI group, suggesting that GAP-43 may serve as a reliable biomarker in the early stages of AD. This study provides evidence supporting the role of GAP-43 as a potential biomarker for AD, particularly in relation to predicting the amyloid pathology pattern in the brain in the MCI stage.